BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37056832)

  • 1. Construction of a prognostic model of luteolin for endometrial carcinoma.
    Zhao J; Jiao W; Sui X; Zou J; Wang J; Lin Z
    Am J Transl Res; 2023; 15(3):2122-2139. PubMed ID: 37056832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
    Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
    Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
    Wang Z; Xing L; Huang Y; Han P
    Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of Oxidative Stress-Related Genes Risk Model Predicts the Prognosis of Uterine Corpus Endometrial Cancer Patients.
    Liu Q; Yu M; Zhang T
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism investigation and experiment validation of capsaicin on uterine corpus endometrial carcinoma.
    Lin Z; Sui X; Jiao W; Chen C; Zhang X; Zhao J
    Front Pharmacol; 2022; 13():953874. PubMed ID: 36210802
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
    Chen Y
    Front Genet; 2022; 13():912037. PubMed ID: 35937995
    [No Abstract]   [Full Text] [Related]  

  • 7. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
    Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
    Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma.
    Zhao L; Fu X; Han X; Yu Y; Ye Y; Gao J
    Cancer Cell Int; 2021 Jan; 21(1):80. PubMed ID: 33509222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma.
    Gu H; Song J; Chen Y; Wang Y; Tan X; Zhao H
    Front Oncol; 2022; 12():923641. PubMed ID: 35719911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening and validation of potential markers associated with uterine corpus endometrial carcinoma and polycystic ovary syndrome based on bioinformatics methods.
    Wu R; Wu C; Zhu B; Li J; Zhao W
    Front Mol Biosci; 2023; 10():1192313. PubMed ID: 37363398
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of an endoplasmic reticulum stress-related gene signature to predict prognosis and potential drugs of uterine corpus endometrial cancer.
    Zhou P; Wu C; Ma C; Luo T; Yuan J; Zhou P; Wei Z
    Math Biosci Eng; 2023 Jan; 20(2):4018-4039. PubMed ID: 36899615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma.
    Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR
    Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of an integrated kinase-related prognostic gene signature associated with tumor immune microenvironment in human uterine corpus endometrial carcinoma.
    Wei S; Zhang J; Shi R; Yu Z; Chen X; Wang H
    Front Oncol; 2022; 12():944000. PubMed ID: 36158685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
    Wang M; Yue S; Yang Z
    Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Analysis of ESRRA in Endometrial Cancer.
    Wang S; Huo X
    Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
    Lu X; Jing L; Liu S; Wang H; Chen B
    Int J Endocrinol; 2022; 2022():5006123. PubMed ID: 35719192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer.
    Liu J; Ji C; Wang Y; Zhang C; Zhu H
    Cancer Cell Int; 2021 Jul; 21(1):365. PubMed ID: 34246261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and verification of an endoplasmic reticulum stress-related prognostic model for endometrial cancer based on WGCNA and machine learning algorithms.
    Lin S; Wei C; Wei Y; Fan J
    Front Oncol; 2024; 14():1362891. PubMed ID: 38725627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
    Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
    J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferroptosis-Related lncRNA for the Establishment of Novel Prognostic Signature and Therapeutic Response Prediction to Endometrial Carcinoma.
    Zhou XY; Dai HY; Zhang H; Zhu JL; Hu H
    Biomed Res Int; 2022; 2022():2056913. PubMed ID: 35937391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.